Living Donor Liver Transplantation

Size: px
Start display at page:

Download "Living Donor Liver Transplantation"

Transcription

1 Trends in Transplantation Transplant. 2010;4: Living Donor Liver Transplantation Juan Carlos García-Valdecasas 1, Itxarone Bilbao Aguirre 2, Ramón Charco Torra 3, Constantino Fondevila Campo 4, Josep Fuster Obregón 5, Juan Carlos García-Valdecasas 1, Paloma Jara Vega 6, Rafael López Andújar 7, Pedro López Cillero 8, Juan Carlos Meneu-Díaz 9, Miguel Navasa Anadón 5 and Fernando Pardo Sánchez 10 1 Department of Surgery, Hospital Clínic i Provincial, Barcelona, Spain; 2 Liver Transplant Unit, Hospital Vall d Hebron, Barcelona, Spain; 3 Department of HPB and Transplant Surgery, Hospital Vall d Hebron, Barcelona, Spain; 4 Division of Gastroenterology and General Surgery, Hospital Clínic i Provincial, Barcelona, Spain; 5 Liver Surgery and Transplantation Unit, Institute of Digestive and Metabolic Diseases,Hospital Clínic i Provincial, Barcelona, Spain; 6 Pediatric Liver Care and Transplant Center, Children s University Hospital, La Paz, Madrid, Spain; 7 Liver Transplantation Unit, Hospital Universitario La Fe, Valencia, Spain; 8 Division of General and Gastrointestinal Surgery, Hospital Reina Sofía, Córdoba, Spain; 9 Division of Gastroenterology and General Surgery, Hospital 12 de Octubre, Madrid, Spain; 10 Department of HPB and Liver Transplant Surgery, Clínica Universidad de Navarra, Pamplona, Spain Abstract Living donor liver transplantation was introduced for the purposes of increasing the number of donors, reducing mortality and morbidity rates, and improving long-term survival of the recipients. The procedure for living donor liver transplantation is the same as for cadaveric liver transplantation. The suitability of potential donors is established following exhaustive evaluations of the donor s liver and overall health. In adult transplantation cases, living donor liver transplantation outcomes are as good as in cadaveric transplants, but donor morbidity continues to be significant as are biliary complications, whereas outcomes in pediatric liver transplants from living donors are more successful than those from cadaveric liver grafts. Living donor liver transplantation is a valid alternative to cadaveric transplantation that can offer improvement of survival rates in the future if we manage to select suitable candidates and overcome a few technical difficulties. (Trends in Transplant. 2010;4:138-44) Corresponding author: Juan Carlos García-Valdecasas, JCVALDE@clinic.ub.es Key words Liver transplantation. Living donor. Pediatric liver transplatation. Adult liver transplatation. Trends in liver transplantation. Correspondence to: Juan Carlos García-Valdecasas Servicio de Cirugía General y Digestiva Hospital Clinic de Barcelona c/ Villarroel, Barcelona, España JCVALDE@clinic.ub.es 138

2 Juan Carlos García-Valdecasas, et al.: Living Donor Liver Transplantation Introduction The main objective of living donor liver transplantation (LDLT) is to increase the number of organs available for transplantation. Although the potential risks to the donor s life are low, they very much govern the performance of this type of transplantation. Nevertheless, the mortality rate for patients on the waiting list for a donor justifies the use of this procedure. This document details the outcomes of discussions held at the consensus meeting of the Spanish groups, whose objective was to detect problems and provide possible solutions. Donation process Trends in living donor transplantation Over the past few years, advances in liver transplantation have allowed the survival rate after one year to rise to nearly 95%. Although Spain has one of the highest transplant rates in the world, availability of cadaveric organs for transplantation is not sufficient at this time to cover existing needs. Waiting list mortality has hovered around 7-8% for the last few years; the probability of undergoing transplantation was 51% in While in recent years a slight increase in living donor kidney transplantations has been observed 1, in LDLT the trend has been in the opposite direction 2. One of the reasons for this decline has been the fact that application of the model for end stage liver disease (MELD) causes the urgency for donations to decrease as patients with a higher risk of death are identified. Other reasons are donor mortality and morbidity rates, the risk of worse outcomes in recipients according to their etiology or the seriousness of their illness, the potential donor evaluation process itself, which means only between 9 and 17% are accepted for donation, as well as issues related to the donors quality of life following transplantation. At this time, LDLT continues to be a complex procedure that involves morbidity and mortality risks for donors as well as risks for recipients due to the need for complex vascular and biliary reconstruction. Nevertheless, the general opinion is that this type of transplantation is justified due to the fact that the waiting list mortality rate still remains too high 3. In addition, the prevalence of hepatocellular carcinoma (HCC) means it is impossible to cover all of the need for liver transplants so that HCC should be considered as an indication criterion for LDLT. Improvement of LDLT requires proper identification of appropriate candidates, such as MELD exceptions or those with HCC, reduction of donor morbidity and mortality and improvement in their quality of life following the donation, compensation for financial loss and, lastly, the introduction of more aggressive options such as programs for crossmatching donor and recipient or programs for use from donors with blood group incompatibility. The majority of LDLT that take place in Spain are being performed in pediatric recipients 4. So far, more than 2,000 implantations of left lateral segment grafts, which is an option that parents frequently request, have been performed worldwide. Selection of potential recipients is based on pediatric endstage liver disease criteria that predict mortality within three months of being included on the waiting list. This modification of the adult score does not appear to identify all of the children in urgent need of transplantation. Those in exceptional situations or serious cases account for approximately 50% of those who receive a transplant. In addition, children over the age of 12 compete with adults, which 139

3 Trends in Transplantation 2010;4 makes giving them priority more difficult. The solution would be to systematically prioritize pediatric patients, giving status as a child whenever necessary and making it an obligation for this pediatric grouping to make division of the graft a priority so as to be able to transplant into both an adult and a child at the same time. The graft will thus have been assigned to two patients and there would be no predominance of one group over the other which, in the majority of cases, is a source of conflict. To maintain the offer of a living donation is also a duty for those parents or relatives who are willing to make a donation. Table 1. Characteristics of the ideal live donor Age: years BMI: < 30 kg/m 2 No cardiopulmonary, renal or metabolic disease Residual liver volume (LLL): > 40% Graft (RLL): > 0,8% recipient weight Steatosis < 20% Favorable anatomical suitability Donor/recipient must be ABO-compatible Significant relationship with the recipient Independence and competence of the donor 140 In some cases, LDLT has been proven to have survival outcomes that are equivalent 5 or superior to full grafts. However, and in spite of being associated with a somewhat greater survival rate, the risk of graft loss is somewhat higher for divided or split grafts than for full ones. Incentives for live donations In order to encourage living donations, the objective must be to reduce to the minimum the negative impact that transplantation has on the donor, as much physically as psychologically or even financially. One of the main drawbacks is the scar, which can be resolved through the use of laparoscopic surgery 6,7. Economic obstacles for the donor could be solved through the creation of protection mechanisms that would guarantee employment maintenance or provide access to long-term care insurance. The majority of hospitals are not candid with patients on the waiting list about the possibility of opting for a LDLT. To improve on this situation in the future, informing patients on the waiting list about this option should be mandatory, as should advising them about referral centers when need be. Donor evaluation The key to LDLT lies mainly in the consideration of the risk to the donor, which should be minimal, and the benefit for the recipient. The donor must weigh the risk of possible mortality, aftereffects, and social, economic, and work aspects. The importance of these factors may vary according to survival of the recipient. The risk of minor complications for the donor is about 27%, that for potentially serious complications that are successfully resolved is 26%, about 2% for lifethreatening conditions, and 0.8% for death 8. Extensive evaluation of the donors is key to achieving good short- and long-term outcomes. The risk of complications in the donor is currently about 37%, about half of which are minor while the remainder are considered to be potentially serious, according to the Clavien classification system. Therefore, one of the most pressing objectives is to try and reduce this number by means of thorough prior testing and a meticulous surgical technique to ensure the highest standard of quality of life for the donor following the operation. Table 1 shows the factors that determine the selection of donors and table 2 shows the protocols for the selection of poten-

4 Juan Carlos García-Valdecasas, et al.: Living Donor Liver Transplantation Table 2. Phases in the process of donor evaluation Preliminary general health evaluation Psychological evaluation Anatomy Overall risks of the surgical procedure First informed consent form Detailed medical history Physical examination Blood tests, blood group, hepatitis serology Mental stability Voluntary nature and willingness Relationship between donor and recipient Informing the donor sufficiently about the surgical procedure Cholangio-MRI CT angiography All-in-one MeVis Lab tests: biochemical, lipid profile, iron, ferritin, transferrin, α1-antitrypsin, ceruloplasmin, immunoglobulin levels, thyroid function tests, tumor markers, coagulation factors Hyper-coagulation profile* Chest X-Ray Lung function test Stress test-ecg Echocardiogram Liver biopsy Presence of steatosis (contraindicated: if > 20% or if 10-20% and RLVBWR < 0,8) Discovery of other histologic findings: (portal and sinusoidal fibrosis; NASH; portal inflammation and necroinflammatory changes) Preparation for surgery Autologous blood donation Second psychological evaluation Evaluation by hepatologist Assessment by anesthetist Final consent Ethics committee Civil registry RLVBWR: remnant liver volume body weight ratio; NASH: nonalcoholic steatohepatitis. *If donor has a history of deep vein thrombosis. in patients with abnormal liver function test results, radiologic abnormalities (steatosis and others), BMI > 30 kg/m 2, or relatives of recipients with primary biliary cirrhosis, primary sclerosing cholangitis or autoimmune disease. tial donors. The donor must be informed of the risks and drawbacks associated with transplantation before giving consent. Despite all this, a comprehensive preoperative evaluation does not guarantee the absence of postoperative morbidity in the donor. The mortality risk for donors is five times greater in LDLT than in living kidney donation 9,10. Progressive experience and improvements in donor selection may reduce mortality and morbidity rates in the future, although they are not expected to ever be as low as in living donor kidney transplantation. The need for total transparency regarding outcomes for donors and awareness that morbidity and mortality rates will never be zero justify the need for establishing a prospective donor morbidity registry and establishing a standard system for recording complications in donors. In the meantime, surgery complications should be recorded following the Clavien classification system or one of the recent adaptations based on it 11. Follow-up of donors is essential and should be made, at the very least, for the first three years following surgery, at a rate of once every three months during the first year and at 12-month intervals after that. It is recommended that the tests to be required should include complete lab tests and volume calculations using magnetic resonance imaging. It is necessary to have a long time of follow-up 141

5 Trends in Transplantation 2010;4 142 of all donors because we don t know what the long-term complications could be. The majority of programs consider that during the first year, follow-up should be performed every three months. Evaluation of the liver The liver is an organ that has surgically important vascular variations, both venous and arterial, in addition to the biliary tract, which makes evaluating it very complex. Current imaging technology is extremely efficient and allows the anatomic distribution of all of its structures, including the biliary tract, to be described with great exactitude. Helical computed tomography with multiplanar reconstruction and magnetic resonance imaging allow the visualization of all of these structures in a single exploration. In addition, the possibility of including a reconstruction of the liver through use of a special program (Me- Vis ) allows three-dimensional images to be obtained that further increase safety in surgical planning. Even so, imaging during the surgical intervention itself must be used to guarantee the anatomical orientation suggested by the preoperative evaluation. In a major surgical procedure, such as that performed on the donor, where meticulous dissection of the hilum of the liver is required, there is no room for guesswork and each step of the process must be performed with the maximum possible safety and knowledge of the possible consequences. Selection of candidates for liver transplantation The ideal candidate for LDLT is a person who would benefit from receiving a cadaveric liver, but who has a low probability of receiving one for transplantation because of the seriousness of their disease, and in addition, is someone who has not previously suffered from significant deterioration in quality of life. At present, the MELD system is able to identify and prioritize those patients with the highest probability of pretransplant death. That is why LDLT currently targets all those patients who are not correctly identified and therefore not prioritized. From our point of view, HCC represents a leading indication for LDLT, both for patients who meet the Milan criteria and for those who exceed these criteria but are known to have a relatively good prognosis (Barcelona criteria, Kyoto criteria, etc.) 12, or those who respond following chemoembolization or radiofrequency ablation and survive for at least three months within the Milan criteria. Donor operation in adult-to-adult and adult-to-child living donor liver transplantation Donor surgery in adult-to-adult procedures In the majority of cases, the surgical technique for the adult donor consists of a right hepatectomy including segments V-VIII, and in which the middle hepatic vein remains with the donor. Donor surgery in adult-to-pediatric recipient procedures The surgical technique for the adult donor normally includes resection of liver segments II and III. Anatomical variability is significantly lower, especially where the bile duct, which is unique in 90% of cases, is concerned. This makes the surgery easier to perform and minimizes the need for bankedblood.

6 Juan Carlos García-Valdecasas, et al.: Living Donor Liver Transplantation Recipient operation in adult-toadult and adult-to-child living donor liver transplantation Recipient surgery in adult-to-adult procedures Vascular reconstruction depends on achieving the best possible venous drainage, which means not only performing anastomosis of the right hepatic vein, but also reconstructing all of the veins, whether they be accessory veins of the right lobe or tributaries of the middle hepatic vein, for which cryopreserved grafts are frequently necessary. Although the artery is small (only 3-5 mm in diameter) its reconstruction rarely causes problems. Continuous hemodynamic monitoring is needed to ensure adequate arterial flow. Last of all come the bile ducts, which have a diameter between 2 and 4 mm and are the Achilles heel of this type of transplantation. The ideal is to perform a systematic duct-to-duct biliary reconstruction, and when this is not possible, to perform a hepaticojejunostomy. Recipient surgery in adult-topediatric recipient procedures Surgical techniques in pediatric living donor transplantation depend largely on the patient s original disease. Vascular reconstruction is essentially the same as in adults, although in this case the size of the liver is always larger than required so that it is not necessary to maneuver to ensure venous drainage. On the contrary, because of its association with congenital anomalies, insufficient portal flow must be ruled out (due to hypoplasia of the portal vein). On the other hand, the size of the bile ducts, which is frequently insufficient, make it necessary to always perform a hepaticojejunostomy, something that is absolutely necessary in cases of biliary atresia. Results Adults As has already been mentioned, the objective of LDLT is to increase the number of donors, reduce mortality and morbidity rates among donors, and improve the longterm survival of recipients. Outcomes for LDLT have improved in the last few years. Although survival rates are now comparable to those from cadaveric donors, the incidence of biliary complications affects long-term outcomes. Nevertheless, according to follow-ups for periods of more than five years in the USA as well as in Europe, the presence of these complications does not appear to affect long-term outcomes. The current trend in Western countries towards progressive reduction of this type of transplantation is not due to poor outcomes, but rather to sporadic cases of donor death, which have led to the closing of LDLT programs at hospitals where these have occurred. There have been a variety causes, from those due to the absence of an appropriate level of care to those where the pressure on the medical staff has had an impact on care delivery. A total of 232 adult and 91 pediatric LDLT were performed in Europe during Both patient and graft survival rates are better in LDLT. Since MELD scores in LDLT patients are lower than in patients receiving cadaveric transplants, there is a need for caution when comparing figures. The experience in Spain is small, although at present the absence of donor mortality associated with good outcomes in both pediatric and adult recipients allow for the consideration of the need for joint action by those hospitals where LDLT is performed in 143

7 Trends in Transplantation 2010;4 order to increase activity. The identification of those patients in need of LDLT is of paramount importance as are systematic information and referral of patients to those centers with the experience, when the case arises. In the last 15 years, 188 LDLT have been performed in Spain 13. As yet no deaths have been recorded, although there has been an 8.3% rate of reoperations to solve complications. Graft survival is similar in patients who are living donor recipients (80% at one year and 65% at five years) as in those who are cadaveric donor recipients (82 and 66%, respectively). The big problem in this type of donation is the high number of complications involved. Living donor liver transplantation in the pediatric population Outcomes in the pediatric age group cause many fewer problems. The family relationship with the child is more reasonable and outcomes are better than those obtained with grafts that come from cadaveric donors. Only the systematic division of all liver grafts would reduce the need for this type of transplantation. Even so, at present living donation allows ensuring absence of mortality on the waiting list, something unthinkable in the 1990s when mortality on the waiting list was around 30%. Between 1993 and 2009, survival of pediatric recipients of living donor transplants in Spain was 84.8% at one year and 79.8% at five years. Final considerations The most important aspects to be resolved in LDLT are the establishment of standardized registries, the resolution of technical difficulties, shortening the learning curve, and improving quality of life for the donor and the efficiency of the procedure. It is also necessary to assess the possibility of expanding indications for LDLT, allowing expected survival in recipients of up to 30%. References 1. Steinbrook R. Public solicitation of organ donors. N Engl J Med. 2005;353: Clavien PA, Dutkowski P, Trotter JF. Requiem for a champion? Living donor liver transplantation. J Hepatol. 2009;51: García-Valdecasas JC, Fuster J, Fondevila C, Calatayud D. Adult living-donor liver transplantation. Gastroenterol Hepatol. 2009;32: ONT. Registro Español de Trasplante Hepático. Memoria de resultados [Spanish Hepatic Transplant Registry. History of results 2009]. Available at: Registros/MEMORIA_RETH_2009.pdf 5. Bourdeaux C, Darwish A, Jamart J, et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. Am J Transplant. 2007;7: Baker TB, Jay CL, Ladner DP, et al. Laparoscopy-assisted and open living donor right hepatectomy: a comparative study of outcomes. Surgery. 2009;146: Suh KS, Yi NJ, Kim T, et al. Laparoscopy-assisted donor right hepatectomy using a hand port system preserving the middle hepatic vein branches. World J Surg. 2009;33: Ghobrial RM, Freise CE, Trotter JF, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology. 2008;135: Brown RS. Live donors in liver transplantation. Gastroenterology. 2008;134: Cotler SJ, McNutt R, Patil R, et al. Adult living donor liver transplantation: Preferences about donation outside the medical community. Liver Transpl. 2001;7: Hata T, Fujimoto Y, Suzuki K, et al. Two cases of central venous catheter-related thrombosis in living liver donors: how can the risk be minimized? Clin Transplant. 2009;23: Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10: SETH-ONT. Memoria de resultados [History of results ]. Available from: 144

Information for patients (and their families) waiting for liver transplantation

Information for patients (and their families) waiting for liver transplantation Information for patients (and their families) waiting for liver transplantation Waiting list? What is liver transplant? Postoperative conditions? Ver.: 5/2017 1 What is a liver transplant? Liver transplantation

More information

Surgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London

Surgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,

More information

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department

More information

Evaluation Process for Liver Transplant Candidates

Evaluation Process for Liver Transplant Candidates Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection

More information

Liver transplantation: Hepatocellular carcinoma

Liver transplantation: Hepatocellular carcinoma Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona

More information

Liver Transplantation

Liver Transplantation 1 Liver Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr History Development of Liver transplantation

More information

Living Donor Liver Transplantation NATCO Introductory Course

Living Donor Liver Transplantation NATCO Introductory Course Living Donor Liver Transplantation NATCO Introductory Course Patricia Harren, RN, ANP, MSN, PNP, CCTC New York Presbyterian Medical Center Center for Liver Disease & Transplant New York, NY Living Donor

More information

Liver Transplantation in Hepatocellular Carcinoma

Liver Transplantation in Hepatocellular Carcinoma Trends in Transplant. 2010;4:51-7 José Fuster, et al.: Liver Transplantation in Hepatocellular Carcinoma Liver Transplantation in Hepatocellular Carcinoma José Fuster, Constantino Fondevila, Santiago Sánchez,

More information

Variations in Surgical Anatomy of the Portal Vein in Living Donor Liver Transplantation

Variations in Surgical Anatomy of the Portal Vein in Living Donor Liver Transplantation Kasr El Aini Journal of Surgery VOL., 9, NO 3 January 2008 19 Variations in Surgical Anatomy of the Portal Vein in Living Donor Liver Transplantation A. Ayad ; W. Tobar; M.Hassan; A.Hosny; M.El Shazly;

More information

pitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel:

pitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel: 11 687 692 2002 pitfall 1078 29 17 9 1 2 3 dislocation outflow block 11 1 2 3 9 1 2 3 4 disorientation pitfall 11 687 692 2002 Tel: 075-751-3606 606-8507 54 2001 8 27 2002 10 31 29 4 pitfall 16 1078 Table

More information

Living Donor Liver Transplantation Wits Donald Gordon Medical Centre

Living Donor Liver Transplantation Wits Donald Gordon Medical Centre Living Donor Liver Transplantation Wits Donald Gordon Medical Centre J Loveland, J Botha, R Britz, B Strobele, A Mahomed, B Bobat, S Rambarran, F van der Schyff et al The First 1963 C Henry Kempe presented

More information

Overall Goals and Objectives for Transplant Hepatology EPAs:

Overall Goals and Objectives for Transplant Hepatology EPAs: Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills

More information

One of the most important problems for patients

One of the most important problems for patients Selection of Donors and Recipients for Living Donor Liver Transplantation Key Points 1. Living donor liver transplantation (LDLT) is increasingly used for adults with end-stage liver disease. 2. Standards

More information

EVALUATION & LISTING. Your Child s Liver Transplant Evaluation. What is the Liver?

EVALUATION & LISTING. Your Child s Liver Transplant Evaluation. What is the Liver? EVALUATION & LISTING Your Child s Liver Transplant Evaluation The University of Michigan is a national leader in liver transplantation, as well as the surgical and medical management of patients with liver

More information

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which

More information

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

PRE-ASSESSMENT. Living Donor Liver Transplantation

PRE-ASSESSMENT. Living Donor Liver Transplantation No. 24 Oct 2003 Before decides to undertake a health technology assessment, a pre-assessment of the literature is performed. Pre-assessments are based on a limited literature search; they are not extensive,

More information

Liver Transplantation

Liver Transplantation Liver Transplantation Dr Mathew Jacob - MRCS FRCS CCT (UK) Lead Consultant HPB/Transplant Surgeon Aster Integrated Liver Care Program AsterMedcity, kochi, kerala, India mathew@transplantationliver.com

More information

Informed Consent for Liver Transplant Patients

Informed Consent for Liver Transplant Patients Informed Consent for Liver Transplant Patients Evaluation Process You will be evaluated with consultations, lab tests and various procedures to determine the medical appropriateness of liver transplant.

More information

UEMS & EBS: DIVISION OF TRANSPLANT SURGERY

UEMS & EBS: DIVISION OF TRANSPLANT SURGERY CURRICULUM AND SYLLABUS TRANSPLANTATION Module 1: Multi-organ retrieval Ability to evaluate donor suitability Ability to retrieve abdominal organs for transplantation Evaluation of donor/ organs suitability

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

Liver Cancer: Diagnosis and Treatment Options

Liver Cancer: Diagnosis and Treatment Options Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver

More information

Live Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease

Live Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease Live Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease Abhi Humar, MD Clinical Director, Thomas E. Starzl Transplantation Institute 1 PITTSBURGH THE BIRTHPLACE OF LIVER TRANSPLANTATION

More information

Staging & Current treatment of HCC

Staging & Current treatment of HCC Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt

More information

HEPATIC METASTASES. We can state 3 types of metastases depending on their treatment options:

HEPATIC METASTASES. We can state 3 types of metastases depending on their treatment options: HEPATIC METASTASES 1. Definition Metastasis means the spread of cancer. Cancerous cells can separate from the primary tumor and enter the bloodstream or the lymphatic system (the one that produces, stores,

More information

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION 1. A service development evaluation to transplant down-staged

More information

Management of Colorectal Liver Metastases

Management of Colorectal Liver Metastases Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver

More information

Ontario s Adult Referral and Listing Criteria for Liver Transplantation

Ontario s Adult Referral and Listing Criteria for Liver Transplantation Ontario s Adult Referral and Listing Criteria for Liver Transplantation Version 3.0 Trillium Gift of Life Network Ontario s Adult Referral & Listing Criteria for Liver Transplantation PATIENT REFERRAL

More information

Current status of hepatic surgery in Korea

Current status of hepatic surgery in Korea Korean J Hepatol. 2009 Dec; 15(Suppl 6):S60 - S64. DOI: 10.3350/kjhep.2009.15.S6.S60 Current status of hepatic surgery in Korea Kyung Sik Kim Department of Surgery, Severance Hospital, Yonsei University

More information

Citation Transplantation Proceedings, 47(3),

Citation Transplantation Proceedings, 47(3), NAOSITE: Nagasaki University's Ac Title Author(s) Hybrid Procedure in Living Donor Li Soyama, Akihiko; Takatsuki, Mitsuhi Tomohiko; Kitasato, Amane; Kinoshit Baimakhanov, Zhassulan; Kuroki, Tam Citation

More information

Liver Transplantation Evaluation: Objectives

Liver Transplantation Evaluation: Objectives Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation

More information

Management of HepatoCellular Carcinoma

Management of HepatoCellular Carcinoma 9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma

More information

Since the first description of living-donor liver transplantation

Since the first description of living-donor liver transplantation CLINICAL AND TRANSLATIONAL RESEARCH Endoscopic Management of Biliary Complications After Adult Living-Donor Versus Deceased-Donor Liver Transplantation Carlos Macías Gómez, 1,4 Jean-Marc Dumonceau, 2 Mariano

More information

Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles

Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles I Congreso de GESIDA Madrid, 21-24 de Octubre del 2009. Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles José M. Miró, 1 Miguel Montejo,

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

The New England Journal of Medicine. Review Article 16,000 14,000 12,000. No. of Patients 10,000 8,000 6,000 4,000 2,000

The New England Journal of Medicine. Review Article 16,000 14,000 12,000. No. of Patients 10,000 8,000 6,000 4,000 2,000 Review Article Medical Progress ADULT-TO-ADULT TRANSPLANTATION OF THE RIGHT HEPATIC LOBE FROM A LIVING DONOR JAMES F. TROTTER, M.D., MICHAEL WACHS, M.D., GREGORY T. EVERSON, M.D., AND IGAL KAM, M.D. TRANSPLANTATION

More information

Liver Cancer And Tumours

Liver Cancer And Tumours Liver Cancer And Tumours What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood from all parts of the body, cancer cells from elsewhere can

More information

What Is the Real Gain After Liver Transplantation?

What Is the Real Gain After Liver Transplantation? LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

Adult-to-adult living donor liver transplantation Triumphs and challenges

Adult-to-adult living donor liver transplantation Triumphs and challenges Falk Symposium No. 163 on Chronic Inflammation of Liver and Gut Adult-to-adult living donor liver transplantation Triumphs and challenges ST Fan, MS, MD, PhD, DSc Professor Sun CY Chair of Hepatobiliary

More information

Management of Rare Liver Tumours

Management of Rare Liver Tumours Gian Luca Grazi Hepato-Biliary-Pancreatic Surgery National Cancer Institute Regina Elena Rome Fibrolamellar Carcinoma Mixed Hepato Cholangiocellular Carcinoma Hepatoblastoma Carcinosarcoma Primary Hepatic

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

National Center for Child Health and Development Organ Transplantation Center

National Center for Child Health and Development Organ Transplantation Center National Center for Child Health and Development Organ Transplantation Center A t the division of transplantation center in NCCHD, we have a mission to save children s life who have been suffered from

More information

Liver transplant for biliary atresia

Liver transplant for biliary atresia Jean de Ville de Goyet ISMETT Director of the Department for the Treatment and Study of Pediatric Abdominal Diseases and Abdominal Transplantation The first human liver transplant was performed on a pediatric

More information

Technique of Split-Liver Transplant for Two Adult Recipients

Technique of Split-Liver Transplant for Two Adult Recipients F'UJIUWA H.EAL,THCAREi, INC. PRESENTS IMAGES mljk?zr 3TUiVU?MAZ7ON Technique of Split-Liver Transplant for Two Adult Recipients Abhinuv Humur, KhuLid Khwuju> Timothy D. SieLu$'John R. Luke, und WiLLium

More information

Evaluation Process for Liver Transplant Candidates

Evaluation Process for Liver Transplant Candidates Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection

More information

Donor Quality Assessment

Donor Quality Assessment Donor Quality Assessment Francesc Moreso, MD, PhD Renal Transplant Unit Hospital Universitari Vall d Hebron Barcelona. Spain 4/9/2017 Donor Quality Assessment 1 What is the problem? Across all age ranges,

More information

Current State of Living Donor Liver Transplantation

Current State of Living Donor Liver Transplantation REVIEW Current State of Living Donor Liver Transplantation Paige M. Porret, Kim M. Olthoff The discrepancy between the number of patients waiting for a liver and the available number of deceased donors

More information

EASL-EORTC Guidelines

EASL-EORTC Guidelines Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according

More information

Candidates about. Lung Allocation Policy. for Transplant. Questions & A n s we r s TA L K I N G A B O U T T R A N S P L A N TAT I O N

Candidates about. Lung Allocation Policy. for Transplant. Questions & A n s we r s TA L K I N G A B O U T T R A N S P L A N TAT I O N TA L K I N G A B O U T T R A N S P L A N TAT I O N Questions & A n s we r s for Transplant Candidates about Lung Allocation Policy U N I T E D N E T W O R K F O R O R G A N S H A R I N G What are the OPTN

More information

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties Patient Education Treatment options This handout describes different kinds of tumors that form in the liver and how they are treated. About the Liver Your liver is the largest organ in your abdomen. It

More information

Optimal Bile Duct Division Using Real- Time Indocyanine Green Near-Infrared Fluorescence Cholangiography During Laparoscopic Donor Hepatectomy

Optimal Bile Duct Division Using Real- Time Indocyanine Green Near-Infrared Fluorescence Cholangiography During Laparoscopic Donor Hepatectomy LETTERS FROM THE FRONTLINE Optimal Bile Duct Division Using Real- Time Indocyanine Green Near-Infrared Fluorescence Cholangiography During Laparoscopic Donor Hepatectomy TO THE EDITOR: Despite advances

More information

Pediatric Liver Transplantation Outcomes in Korea

Pediatric Liver Transplantation Outcomes in Korea ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/6/jkms.8..4 J Korean Med Sci 0; 8: 4-47 Pediatric Liver Transplantation Outcomes in Korea Jong Man Kim,, * Kyung Mo Kim,, * Nam-Joon

More information

Paediatric Liver Transplant Programme Wits Donald Gordon Medical Centre

Paediatric Liver Transplant Programme Wits Donald Gordon Medical Centre Paediatric Liver Transplant Programme Wits Donald Gordon Medical Centre J Loveland, J Botha, R Britz, B Strobele, S Rambarran, A Terblanche, C Kock, P Walabh, M Beretta, M Duncan et al 1817 reveal the

More information

Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation

Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation 8 Original Article Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation Neema Kaseje 1 Samuel Lüthold 2 Gilles Mentha 3 Christian Toso 3 Dominique Belli 2 Valérie McLin 2 Barbara

More information

Vascular Imaging in the Pediatric Abdomen. Jonathan Swanson, MD

Vascular Imaging in the Pediatric Abdomen. Jonathan Swanson, MD Vascular Imaging in the Pediatric Abdomen Jonathan Swanson, MD Goals and Objectives To understand the imaging approach, appearance, and clinical manifestations of the common pediatric abdominal vascular

More information

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT

More information

How to integrate surgery in the treatment of patients with liver-only metastatic disease

How to integrate surgery in the treatment of patients with liver-only metastatic disease How to integrate surgery in the treatment of patients with liver-only metastatic disease Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB)

More information

Related Policies None

Related Policies None Medical Policy MP 7.03.06 BCBSA Ref. Policy: 7.03.06 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies None DISCLAIMER Our medical policies are designed for informational

More information

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies

More information

Surgery for hilar cholangiocirconoma

Surgery for hilar cholangiocirconoma Department of Surgery University Hospital RWTH Aachen Surgery for hilar cholangiocirconoma Ulf Peter Neumann Agenda Operating on the most complex tumor in HBP Surgery Preoperative management Does the patient

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

Living donor liver transplantation: Eastern experiences

Living donor liver transplantation: Eastern experiences Living donor liver transplantation: Eastern experiences K Tanaka 1, Y Ogura 1, T Kiuchi 1, Y Inomata 2, S Uemoto 3 and H Furukawa 4 "Deportment of Transplantation and Immunology, Kyoto University Hospital,

More information

HOW I DO IT Feasibility of Bisegmentectomy 7 8 is Independent of the Presence of a Large Inferior Right Hepatic Vein

HOW I DO IT Feasibility of Bisegmentectomy 7 8 is Independent of the Presence of a Large Inferior Right Hepatic Vein Journal of Surgical Oncology 2006;93:338 342 HOW I DO IT Feasibility of Bisegmentectomy 7 8 is Independent of the Presence of a Large Inferior Right Hepatic Vein MARCEL AUTRAN C. MACHADO, MD, 1,2 * PAULO

More information

Experience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010

Experience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010 Original articles Experience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010 Octavio Muñoz, MD, 1 Laura Ovadía, MD,

More information

Understanding Liver Disease

Understanding Liver Disease Visit us on the Web at: clevelandclinic.org/liver To make an appointment call: 888.410.1775, option 1 International patients call: 001.216.444.8184 WOULD YOU LIKE A SECOND OPINION? If you would like a

More information

Original article: new surgical approaches to the Klatskin tumour

Original article: new surgical approaches to the Klatskin tumour Alimentary Pharmacology & Therapeutics Original article: new surgical approaches to the Klatskin tumour T. M. VAN GULIK*, S. DINANT*, O. R. C. BUSCH*, E. A. J. RAUWS, H. OBERTOP* & D. J. GOUMA Departments

More information

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic

More information

Post-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options

Post-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options Post-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options Poster No.: C-1501 Congress: ECR 2015 Type: Educational Exhibit Authors: A. Hadjivassiliou,

More information

University of Colorado Health Sciences Center, Denver Colorado ******************** ******************

University of Colorado Health Sciences Center, Denver Colorado ******************** ****************** University of Colorado Health Sciences Center, Denver Colorado ******************** 1988-2005 ****************** Disclosures No disclosures Case 53 M presents with sudden onset of upper abdominal pain

More information

Liver Transplant. Description

Liver Transplant. Description Subject: Liver Transplant Page: 1 of 27 Last Review Status/Date: March 2014 Liver Transplant Description Background Recipients Liver transplantation is now routinely performed as a treatment of last resort

More information

Revised Annual Program Volumes for ASTS Accreditation Approved May 2013 Revised June 2016

Revised Annual Program Volumes for ASTS Accreditation Approved May 2013 Revised June 2016 Overview This document outlines new requirements and processes for ASTS accreditation of transplant surgery fellowships including volume requirements for ASTS accreditation, as well as the individual training

More information

Vascular Technology Examination Content Outline

Vascular Technology Examination Content Outline Vascular Technology Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 Normal Anatomy, Perfusion, and Function Evaluate normal anatomy, perfusion, function 2 Pathology, Perfusion,

More information

Hepatocellular Carcinoma: Clinical Priorities from Detection to Liver Transplantation

Hepatocellular Carcinoma: Clinical Priorities from Detection to Liver Transplantation Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatocellular-carcinomaclinical-priorities-detection-liver-transplantation/7948/

More information

Early Outcome of Donors in Living-Donor Liver Transplantation at King Hussein Medical Center

Early Outcome of Donors in Living-Donor Liver Transplantation at King Hussein Medical Center Early Outcome of Donors in Living-Donor Liver Transplantation at King Hussein Medical Center Salah Halasa MD*, Sahim Qusouss MD* ABSTRACT Objectives: To evaluate the safety and early outcome of donors

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

MEDICAL MANAGEMENT POLICY

MEDICAL MANAGEMENT POLICY PAGE: 1 of 5 MEDICAL MANAGEMENT POLICY This medical policy is not a guarantee of benefits or coverage, nor should it be deemed as medical advice. In the event of any conflict concerning benefit coverage,

More information

Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison

Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 722-727 Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison Georgios

More information

Successful Application of Supraceliac Aortohepatic Conduit Using Saphenous Venous Graft in Right Lobe Living Donor Liver Transplantation

Successful Application of Supraceliac Aortohepatic Conduit Using Saphenous Venous Graft in Right Lobe Living Donor Liver Transplantation LETTERS FROM THE FRONTLINE Successful Application of Supraceliac Aortohepatic Conduit Using Saphenous Venous Graft in Right Lobe Living Donor Liver Transplantation TO THE EDITOR: Hepatic artery (HA) reconstruction

More information

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob: Diseases of liver Dr. Mohamed. A. Mahdi Mob: 0123002800 4/2/2019 Cirrhosis Cirrhosis is a complication of many liver disease. Permanent scarring of the liver. A late-stage liver disease. The inflammation

More information

9th Paris Hepatitis Conference

9th Paris Hepatitis Conference 9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units

More information

Abdomen Sonography Examination Content Outline

Abdomen Sonography Examination Content Outline Abdomen Sonography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 Anatomy, Perfusion, and Function Pathology, Vascular Abnormalities, Trauma, and Postoperative Anatomy

More information

Related Policies: None

Related Policies: None Medical Policy MP 7.03.06 Original Policy Date: December 1995 Last Review: 09/28/2017 Effective Date: 11/15/2017 Section: Surgery End Date: Related Policies: None Disclaimer Our medical policies are designed

More information

Your Health Matters. What You Need to Know about Adult Liver Transplantation. Access our patient education library online at

Your Health Matters. What You Need to Know about Adult Liver Transplantation. Access our patient education library online at Access our patient education library online at www.ucsfhealth.org Your Health Matters What You Need to Know about Adult Liver Transplantation Table of Contents 1. Introduction 2. The Preliminary Process

More information

Clinical Policy: Pediatric Liver Transplant

Clinical Policy: Pediatric Liver Transplant Clinical Policy: Reference Number: CP.MP.120 Last Review Date: 04/18 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

Liver Transplantation for HCC Which Criteria?

Liver Transplantation for HCC Which Criteria? Liver Transplantation for HCC Which Criteria? Jacques Belghiti - François Durand Claire Francoz Hepato-Biliary-Pancreatic Liver Surgery and Liver Transplantation Unit Hôpital Beaujon (AP-HP), Clichy -

More information

Corporate Medical Policy Liver Transplant and Combined Liver-Kidney Transplant

Corporate Medical Policy Liver Transplant and Combined Liver-Kidney Transplant Corporate Medical Policy Liver Transplant and Combined Liver-Kidney Transplant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: liver_transplant_and_combined_liver_kidney_transplant

More information

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer

More information

POST TRANSPLANT OUTCOMES IN PSC

POST TRANSPLANT OUTCOMES IN PSC POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners

More information

LiverGroup.org. Case Report Form (CRF) for STAGED procedures

LiverGroup.org. Case Report Form (CRF) for STAGED procedures Case Report Form (CRF) for STAGED procedures Patient Characteristics Case number * Age * ( 18)y Gender * Male Female Race * Caucasian Asian African Other If other race, please specify Height * cm Weight

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

Chronic liver failure Assessment for liver transplantation

Chronic liver failure Assessment for liver transplantation Chronic liver failure Assessment for liver transplantation Liver Transplantation Dealing with the organ shortage Timing of listing must reflect length on waiting list Ethical issues Justice, equity, utility

More information

What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured

What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured What Is Cirrhosis? Cirrhosis occurs when the liver is permanently scarred or injured by chronic conditions and diseases. Common causes of cirrhosis include: Long-term alcohol abuse. Chronic viral hepatitis

More information

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network

More information

Liver Transplant MM /21/1999. HMO; PPO 09/01/2014 Section: Transplants Place(s) of Service: Inpatient

Liver Transplant MM /21/1999. HMO; PPO 09/01/2014 Section: Transplants Place(s) of Service: Inpatient Liver Transplant Policy Number: Original Effective Date: MM.07.023 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO 09/01/2014 Section: Transplants Place(s) of Service: Inpatient Precertification

More information

Corporate Medical Policy Liver Transplant

Corporate Medical Policy Liver Transplant Corporate Medical Policy Liver Transplant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: liver_transplant 12/1995 5/2017 5/2018 5/2017 Description of Procedure or Service Liver

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

Biliary Anatomy in Living-related Liver Transplantation

Biliary Anatomy in Living-related Liver Transplantation The 5th IHPBA Congress - Istanbul Biliary Anatomy in Living-related Liver Transplantation biliary trees hilar plate Assessment for Vascular Anatomy 1. 3DCT portal vein hepatic vein hepatic artery 2. No

More information

Organ Allocation in Pennsylvania: Current concepts and future directions

Organ Allocation in Pennsylvania: Current concepts and future directions Organ Allocation in Pennsylvania: Current concepts and future directions David Goldberg, MD, MSCE Assistant Professor of Medicine and Epidemiology Medical Director of Living Donor Liver Transplantation

More information